Finding 496786 (2023-002)

Significant Deficiency Repeat Finding
Requirement
L
Questioned Costs
-
Year
2023
Accepted
2024-09-13
Audit: 319539
Organization: Overdose Lifeline, Inc. (IN)
Auditor: Pile CPAS

AI Summary

  • Core Issue: The Schedule of Expenditures of Federal Awards (SEFA) has improved but still contains inaccuracies and omissions, affecting its reliability.
  • Impacted Requirements: Federal regulations and GAAP mandate a complete and accurate SEFA, which is crucial for compliance and future funding eligibility.
  • Recommended Follow-Up: Management should enhance SEFA processes, provide ongoing training for staff, and regularly update procedures to ensure accuracy and adherence to best practices.

Finding Text

Finding 2023-002 Schedule of Expenditures of Federal Awards Preparation Type of Finding: Significant Deficiency over Financial Reporting. Criteria: Federal regulations and GAAP require the preparation of a comprehensive and accurate Schedule of Expenditures of Federal Awards ("SEFA"), which includes transparent disclosure of federal funds expended, including the source of funds, program titles, award numbers, and expenditure amounts. Condition: This year’s audit revealed significant improvements in the Organization’s SEFA preparation. The SEFA now more accurately reflects federal awards received and expended, and there have been enhancements in documenting award numbers, funding sources, and program titles. However, some inaccuracies and omissions persist, impacting the completeness and reliability of the SEFA. Cause: Ongoing gaps in the skills, knowledge, and experience of personnel responsible for SEFA preparation and reporting contribute to the persistence of some inaccuracies. Continued deficiencies in training and procedural adherence are factors in these issues. Possible or Known Effect: While improvements have mitigated the risk of misrepresentation, the remaining discrepancies could still lead to misinterpretation of federal funds received and expended. This could affect the Organization’s compliance with federal reporting requirements and potentially impact eligibility for future federal funding. Questioned Costs: There were no questioned costs identified. Repeat Finding: This finding is a repeat from the prior year. The previous finding number was 2022-002. Recommendation: Management should continue to build on recent improvements by further refining SEFA preparation processes. Enhanced controls should be implemented to ensure complete and accurate recording of federal awards and expenditures. Ongoing training for financial reporting personnel should be sustained, addressing remaining knowledge gaps and procedural issues. Documented procedures should be reviewed and updated regularly to ensure adherence to best practices and continuous improvement in SEFA preparation. Views of Responsible Officials: The Organizations’ Board and Executive Team consisting of the Chief Executive Officer (CEO) and the Chief Operating Officer (COO) and key Overdose Lifeline (ODL) Staff to include the independent bookkeeper and Grant and Finance Manager recognize the need to further refine the SEFA preparation process. This will be accomplished through the completion of a formal course that covers performing a single audit and consultation with the Independent Public Accounting Firm (Pile CPAs).

Categories

Reporting

Other Findings in this Audit

  • 496767 2023-001
    Material Weakness
  • 496768 2023-002
    Significant Deficiency Repeat
  • 496769 2023-004
    Significant Deficiency
  • 496770 2023-003
    Significant Deficiency Repeat
  • 496771 2023-005
    Material Weakness
  • 496772 2023-001
    Material Weakness
  • 496773 2023-002
    Significant Deficiency Repeat
  • 496774 2023-004
    Significant Deficiency
  • 496775 2023-003
    Significant Deficiency Repeat
  • 496776 2023-001
    Material Weakness
  • 496777 2023-002
    Significant Deficiency Repeat
  • 496778 2023-004
    Significant Deficiency
  • 496779 2023-001
    Material Weakness
  • 496780 2023-002
    Significant Deficiency Repeat
  • 496781 2023-004
    Significant Deficiency
  • 496782 2023-001
    Material Weakness
  • 496783 2023-002
    Significant Deficiency Repeat
  • 496784 2023-004
    Significant Deficiency
  • 496785 2023-001
    Material Weakness
  • 496787 2023-004
    Significant Deficiency
  • 496788 2023-001
    Material Weakness
  • 496789 2023-002
    Significant Deficiency Repeat
  • 496790 2023-004
    Significant Deficiency
  • 496791 2023-001
    Material Weakness
  • 496792 2023-002
    Significant Deficiency Repeat
  • 496793 2023-004
    Significant Deficiency
  • 496794 2023-001
    Material Weakness
  • 496795 2023-002
    Significant Deficiency Repeat
  • 496796 2023-004
    Significant Deficiency
  • 1073209 2023-001
    Material Weakness
  • 1073210 2023-002
    Significant Deficiency Repeat
  • 1073211 2023-004
    Significant Deficiency
  • 1073212 2023-003
    Significant Deficiency Repeat
  • 1073213 2023-005
    Material Weakness
  • 1073214 2023-001
    Material Weakness
  • 1073215 2023-002
    Significant Deficiency Repeat
  • 1073216 2023-004
    Significant Deficiency
  • 1073217 2023-003
    Significant Deficiency Repeat
  • 1073218 2023-001
    Material Weakness
  • 1073219 2023-002
    Significant Deficiency Repeat
  • 1073220 2023-004
    Significant Deficiency
  • 1073221 2023-001
    Material Weakness
  • 1073222 2023-002
    Significant Deficiency Repeat
  • 1073223 2023-004
    Significant Deficiency
  • 1073224 2023-001
    Material Weakness
  • 1073225 2023-002
    Significant Deficiency Repeat
  • 1073226 2023-004
    Significant Deficiency
  • 1073227 2023-001
    Material Weakness
  • 1073228 2023-002
    Significant Deficiency Repeat
  • 1073229 2023-004
    Significant Deficiency
  • 1073230 2023-001
    Material Weakness
  • 1073231 2023-002
    Significant Deficiency Repeat
  • 1073232 2023-004
    Significant Deficiency
  • 1073233 2023-001
    Material Weakness
  • 1073234 2023-002
    Significant Deficiency Repeat
  • 1073235 2023-004
    Significant Deficiency
  • 1073236 2023-001
    Material Weakness
  • 1073237 2023-002
    Significant Deficiency Repeat
  • 1073238 2023-004
    Significant Deficiency

Programs in Audit

ALN Program Name Expenditures
93.137 Community Programs to Improve Minority Health Grant Program $56,493
93.788 Opioid Str $19,750
21.027 Coronavirus State and Local Fiscal Recovery Funds $18,541